Treatment-Resistant Schizophrenia: Definition, Predictors, and Therapy Options

Area of Science:

• Psychiatry
• Pharmacology

Background:

• Treatment-resistant schizophrenia (TRS) is defined by nonresponse to at least two antipsychotic trials.
• Predictors for TRS include demographic, clinical, and neurological factors.
• TRS can be primary (early) or secondary (later-onset).

Purpose of the Study:

• To highlight clozapine as the most effective treatment for TRS.
• To discuss barriers to clozapine use and the benefits of earlier initiation.
• To provide guidance on clozapine monitoring and therapeutic drug monitoring.

Main Methods:

• Review of existing literature and guidelines on TRS treatment.
• Analysis of factors influencing clozapine efficacy and plasma levels.
• Discussion of clozapine's side effect profile and management.

Main Results:

• Clozapine is the gold standard for TRS, with higher response rates when initiated early.
• Barriers to clozapine use exist but can be overcome.
• Side effects are manageable with proactive monitoring and intervention.
• Therapeutic drug monitoring is recommended for optimal dosing (≥350 µg/L).
• Factors like smoking, caffeine, sex, obesity, inflammation, and age affect plasma clozapine levels.

Conclusions:

• Earlier and broader use of clozapine is crucial for improving outcomes in TRS.
• Effective management of TRS requires understanding predictors, optimizing clozapine therapy, and monitoring side effects.